[Vienna, April 8, 2026] — In a transformative move set to advance the landscape of urological oncology, the European Association of Nuclear Medicine (EANM) has been officially announced as a co-organiser of the European Multidisciplinary Congress on Urological Cancers (EMUC26). This strategic collaboration marks a pivotal moment, integrating nuclear medicine’s cutting-edge innovations directly into the forefront of urological cancer healthcare and research. The upcoming congress, scheduled for November 5-8, 2026, in Brussels, Belgium, will embrace a multidisciplinary ethos by including EANM alongside the European Association of Urology (EAU), European Society of Radiology (ESR), and European Society for Radiotherapy and Oncology (ESTRO) in a unified endeavour to improve outcomes for patients across Europe and beyond.
This development amplifies the critical role that nuclear medicine, particularly molecular imaging and theranostics, plays in the diagnosis, staging, and treatment of urological malignancies. Over recent years, the advent of highly specific imaging modalities like Prostate-Specific Membrane Antigen (PSMA) PET/CT has revolutionized prostate cancer management. By providing unparalleled sensitivity and specificity, PSMA PET/CT enables earlier detection of metastatic lesions and more accurate disease staging than conventional imaging counterparts. This has profound implications not only for patient outcomes but also for clinical decision-making processes regarding therapeutic interventions.
The rising prominence of radioligand therapy, an emerging molecularly targeted treatment method, adds another layer of innovation to urological cancer care. By harnessing radionuclides conjugated to ligands that target tumor-specific biomarkers such as PSMA, these treatments deliver lethal radiation doses directly to malignant cells while sparing surrounding healthy tissue. This precision holds particular promise for patients with advanced or treatment-refractory prostate cancer, offering new avenues where traditional hormone therapies or chemotherapy may falter.
EANM’s co-organisation role is more than symbolic—it promises an enriched congress agenda where breakthroughs in nuclear medicine will be intricately woven into the wider clinical discussions. EMUC26’s sessions will encompass molecular imaging advances, novel radioligand therapies, and their integration into combined treatment regimens. Attendees, including urologists, radiologists, nuclear medicine specialists, radiation oncologists, and allied healthcare professionals, will participate in scientifically rigorous workshops and interactive case-based discussions, fostering a collaborative environment tailored to cross-disciplinary innovation.
The multidisciplinary nature of EMUC26 epitomizes modern oncological care’s direction, recognizing that optimal patient management requires synchronized expertise across specialties. EANM President Paola Anna Erba emphasizes this paradigm, underscoring the commitment to precision medicine approaches that extend from diagnosis through to personalized treatment and follow-up. This alignment will build momentum toward standardized protocols that incorporate functional imaging biomarkers alongside morphological data to refine risk assessment and therapeutic stratification.
From a technical perspective, molecular imaging modalities offered by nuclear medicine provide functional insights into tumor biology that traditional anatomical imaging cannot. PSMA PET/CT, for example, exploits the enzyme overexpression characteristic of prostate carcinoma cells, enabling visualization of microscopic disease earlier and with increased clarity. Such advances lower the likelihood of both understaging and overtreatment. Additionally, emerging tracers under investigation seek to broaden this molecular imaging utility to other urological malignancies, including bladder and renal cancers, which have seen comparatively slower progress.
Equally, theranostic strategies embody a dual diagnostic-therapeutic approach, optimizing patient selection through companion imaging agents before administering radioligand therapies. This tailor-made treatment delivers radionuclides such as Lutetium-177 or Actinium-225 directly to tumor sites, achieving cytotoxic effects with a measured safety profile. Current clinical trials reviewed during EMUC26 will shed light on efficacy data, dosimetry advances, and potential resistance mechanisms, fueling scholarly debate and innovation.
EMUC26’s carefully curated program supports knowledge dissemination not only through formal lectures but also via interactive learning—vital for translating complex nuclear medicine techniques into routine clinical practice. This embedded educational component ensures that advancements in molecular diagnostics and targeted radiotherapy are accessible to urologists and oncologists who may not specialize in nuclear medicine but whose clinical decisions rely on its insights.
Over four action-packed days, the congress will facilitate exchange of ideas, case evaluations, and the exploration of integrative workflows that synergize cross-specialty expertise. This forum is vital in overcoming historic silos between radiology, urology, oncology, and nuclear medicine, striving toward unified care pathways that leverage each discipline’s strengths.
Importantly, the deadline for abstract submissions is set for August 1, 2026, signaling an open invitation for researchers and clinicians worldwide to contribute original findings and clinical experiences that push the boundaries of understanding in genitourinary oncology. Active participation is encouraged to foster multidisciplinary collaborations that translate scientific discoveries into practical improvements in treatment algorithms.
EANM’s involvement not only elevates the scientific rigor of EMUC26 but also positions molecular imaging and theranostics firmly within mainstream urological cancer discourse. By merging these specialties under a common umbrella, the congress embodies the future of oncology—a landscape defined by technological sophistication, precision therapies, and collaborative care models designed to improve survival and quality of life for patients affected by these challenging diseases.
For those eager to connect and engage, registration for EMUC26 is currently open, with detailed information available on the official congress website. The initiative welcomes healthcare professionals, scientists, and stakeholders committed to shaping the next frontier in urological cancer care.
Subject of Research:
Article Title:
News Publication Date:
Web References:
References:
Image Credits:
Keywords:
Nuclear medicine; molecular imaging; PSMA PET/CT; radioligand therapy; theranostics; prostate cancer; urological cancers; multidisciplinary oncology; EMUC26; European Association of Nuclear Medicine; EANM; European Multidisciplinary Congress on Urological Cancers; precision medicine; radiology; oncology
Tags: advanced diagnostic imaging for cancer stagingEMUC26 urological cancer congressEuropean Association of Nuclear Medicine partnershipEuropean urology and nuclear medicine collaborationintegrated cancer research in Europemolecular imaging in urological malignanciesmultidisciplinary urological oncology congressnuclear medicine innovations in cancer careprostate cancer metastatic lesion detectionPSMA PET/CT prostate cancer imagingtheranostics in urological cancer treatmenturological cancer patient outcome improvement
